Top Markets
#1 NKN NKN +185.61%
#2 Black Phoenix Black Phoenix +99.33%
#3 Liquid Mercury Liquid Mercury +33.08%
#4 Codatta Codatta +28.59%
#5 Saakuru Saakuru +25.06%
#6 Particle Network Particle Network +17.23%
#7 Bedrock Bedrock +15.78%
#8 StakeStone StakeStone +14.95%
#9 Janction Janction +14.79%
#10 Arcblock Arcblock +14.20%
Coin of the day
NKN NKN
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Classifica tra le azioni #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prezzo delle azioni
$206.50
Capitalizzazione di mercato
$365.13B
Variazione (1 giorno)
-0.31%
Variazione (1 anno)
2.58%
Paese
US
Scambia AbbVie Inc. (ABBV)

Categoria

Healthcare
Numero di azioni in circolazione per AbbVie Inc. (ABBV)
Numero di azioni in circolazione al December 2025: 1.78B
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di AbbVie Inc., il numero attuale di azioni in circolazione è 1.78B. Alla fine del December 2024, la società aveva 1.77B azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di AbbVie Inc. (ABBV) dal 2009 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
2026 (TTM) 1.78B -0.57%
2025 1.79B 1.23%
2024 1.77B 0.06%
2023 1.77B -0.17%
2022 1.77B 0.06%
2021 1.77B 6.18%
2020 1.67B 12.56%
2019 1.48B -3.89%
2018 1.54B -3.45%
2017 1.60B -1.60%
2016 1.62B -0.18%
2015 1.63B 1.88%
2014 1.60B 0.38%
2013 1.59B 0.76%
2012 1.58B -2.41%
2011 1.62B 0.00%
2010 1.62B 0.00%
2009 1.62B 0.00%
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
 898.00M -49.56%
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
 3.10B 74.12%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 2.43B 36.41%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
 1.91B 7.45%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 2.49B 39.85%
US